Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

被引：18

作者：

George, Daniel J. ^{[1
]}

Hessel, Colin ^{[2
]}

Halabi, Susan ^{[3
,4
]}

Michaelson, M. Dror ^{[5
]}

Hahn, Olwen ^{[6
]}

Walsh, Meghara ^{[7
]}

Picus, Joel ^{[8
]}

Small, Eric J. ^{[9
]}

Dakhil, Shaker ^{[10
]}

Feldman, Darren R. ^{[11
]}

Mangeshkar, Milan ^{[2
]}

Scheffold, Christian ^{[2
]}

Morris, Michael J. ^{[11
]}

Choueiri, Toni K. ^{[7
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[2] Exelixis Inc, Alameda, CA USA

[3] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Alliance Protocol Operat Off, Chicago, IL USA

[7] Dana Farber Partners CancerCare, Boston, MA USA

[8] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Univ Kansas Wichita, Wichita, KS USA

[11] Memorial Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2019年 / 24卷 / 11期

关键词：

THERAPY;

D O I：

10.1634/theoncologist.2019-0316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

引用

页码：1497 / 1501

页数：5

共 50 条

[21] Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).
Escudier, Bernard J.
Motzer, Robert J.
Powles, Thomas
Tannir, Nizar M.
Davis, Ian D.
Donskov, Frede
Grunwald, Viktor
Heng, Daniel Yick Chin
Hutson, Thomas
Melichar, Bohuslav
Nosov, Dimitry
Rini, Brian I.
Salman, Pamela
Sternberg, Cora N.
Szczylik, Cezary
Wolter, Pascal
Arroyo, Alan M.
Mangeshkar, Milan
Agarwal, Neeraj
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[22] Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Rini, Brian, I
Motzer, Robert J.
Powles, Thomas
McDermott, David F.
Escudier, Bernard
Donskov, Frede
Hawkins, Robert
Bracarda, Sergio
Bedke, Jens
De Giorgi, Ugo
Porta, Camillo
Ravaud, Alain
Parnis, Francis
Grande, Enrique
Zhang, Wei
Huseni, Mahrukh
Carroll, Susheela
Sufan, Roxana
Schiff, Christina
Atkins, Michael B.
EUROPEAN UROLOGY, 2021, 79 (05) : 659 - 662
[23] CheckMate 214 Retrospective Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients With Previously Untreated Advanced Renal Cell Carcinoma With Sarcomatoid Features
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 6 - 8
[24] A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
Reinhorn, Daniel
Sarfaty, Michal
Leshno, Moshe
Moore, Assaf
Neiman, Victoria
Rosenbaum, Eli
Goldstein, Daniel A.
ONCOLOGIST, 2019, 24 (03): : 366 - 371
[25] Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma
Liu, Yanjie
Meng, Ying
Li, Mengmeng
Dong, Yanjiao
ARCHIVOS ESPANOLES DE UROLOGIA, 2024, 77 (05): : 584 - 590
[26] Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
Kim, Jwa Hoon
Park, Inkeun
Lee, Jae Lyun
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 325 - 332
[27] Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
Jwa Hoon Kim
Inkeun Park
Jae Lyun Lee
Cancer Chemotherapy and Pharmacology, 2016, 78 : 325 - 332
[28] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Benjamin Duy Tran
Jing Li
Neang Ly
Raffaella Faggioni
Lorin Roskos
Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
[29] PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Flaifel, Abdallah
Xie, Wanling
Braun, David A.
Ficial, Miriam
Bakouny, Ziad
Nassar, Amin H.
Jennings, Rebecca B.
Escudier, Bernard
George, Daniel J.
Motzer, Robert J.
Morris, Michael J.
Powles, Thomas
Wang, Evelyn
Huang, Ying
Freeman, Gordon J.
Choueiri, Toni K.
Signoretti, Sabina
CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6080 - 6088
[30] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
Choueiri, T.
Escudier, B.
Powles, T.
Mainwaring, P.
Rini, B.
Donskov, F.
Hammers, H.
Hutson, T.
Roth, B.
Peltola, K.
Lee, J. L.
Heng, D.
Schmidinger, M.
Borgman-Hagey, A.
Hessel, C.
Scheffold, C.
Schwab, G.
Tannir, N.
Motzer, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709

← 1 2 3 4 5 →